Implications of ATP-binding cassette transporters for brain pharmacotherapies.

[1]  J. Fritschy,et al.  Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood–brain barrier , 2006, Neuroscience.

[2]  Satoshi Murakami,et al.  Crystal structures of a multidrug transporter reveal a functionally rotating mechanism , 2006, Nature.

[3]  S. Cole,et al.  Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. , 2006, Physiological reviews.

[4]  Hiroyuki Hirano,et al.  A New Strategy of High-Speed Screening and Quantitative Structure-Activity Relationship Analysis to Evaluate Human ATP-Binding Cassette Transporter ABCG2-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.

[5]  E. Kılıç,et al.  Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia , 2006, Nature Neuroscience.

[6]  J. Simard,et al.  Newly expressed SUR1-regulated NCCa-ATP channel mediates cerebral edema after ischemic stroke , 2006, Nature Medicine.

[7]  M. Wada.  Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response. , 2006, Cancer letters.

[8]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[9]  Yuichi Sugiyama,et al.  In Vivo Evaluation of P-glycoprotein Function at the Blood-Brain Barrier in Nonhuman Primates Using [11C]Verapamil , 2006, Journal of Pharmacology and Experimental Therapeutics.

[10]  I. Poggesi,et al.  Computational models for identifying potential P-glycoprotein substrates and inhibitors. , 2006, Molecular pharmaceutics.

[11]  Masahiko Watanabe,et al.  Distinct spatio‐temporal expression of ABCA and ABCG transporters in the developing and adult mouse brain , 2005, Journal of neurochemistry.

[12]  E. Aronica,et al.  Expression of Multidrug Transporters MRP1, MRP2, and BCRP Shortly after Status Epilepticus, during the Latent Period, and in Chronic Epileptic Rats , 2005, Epilepsia.

[13]  T. Ishikawa,et al.  Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design , 2005, Naturwissenschaften.

[14]  S. Cole,et al.  Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1) , 2005, Pharmacogenetics and genomics.

[15]  Roman Rouzier,et al.  Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma , 2005, Cancer.

[16]  S. Cole,et al.  Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. , 2005, Pharmacogenetics and genomics.

[17]  Wolfgang Löscher,et al.  Drug resistance in brain diseases and the role of drug efflux transporters , 2005, Nature Reviews Neuroscience.

[18]  D. Mankoff,et al.  Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography , 2005, Clinical pharmacology and therapeutics.

[19]  W. Löscher,et al.  Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. , 2005, Brain : a journal of neurology.

[20]  D. Piwnica-Worms,et al.  Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  D. Keppler,et al.  Expression and immunolocalization of the multidrug resistance proteins, MRP1–MRP6 (ABCC1–ABCC6), in human brain , 2004, Neuroscience.

[22]  M. Laakso,et al.  Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study. , 2004, The Journal of clinical endocrinology and metabolism.

[23]  S. Nishimura,et al.  Pharmacokinetic animal PET study of FK506 as a potent neuroprotective agent. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  Donald W. Miller,et al.  Plasma Membrane Localization of Multidrug Resistance-Associated Protein Homologs in Brain Capillary Endothelial Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[25]  D. Begley.  Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. , 2004, Pharmacology & therapeutics.

[26]  J. Beijnen,et al.  Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. , 2004, European journal of cancer.

[27]  S. Cisternino,et al.  Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. , 2004, Cancer research.

[28]  M. Fromm,et al.  Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. , 2004, Pharmacogenetics.

[29]  Thierry Buclin,et al.  Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance , 2004, Clinical pharmacology and therapeutics.

[30]  G. Gerrard,et al.  Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. , 2004, Haematologica.

[31]  J. Beijnen,et al.  The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice , 2004, Cancer Chemotherapy and Pharmacology.

[32]  U. Brinkmann,et al.  Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. , 2003, The American journal of pathology.

[33]  Richard E Carson,et al.  Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  C. Boyd,et al.  The Distribution of Abcc6 in Normal Mouse Tissues Suggests Multiple Functions for this ABC Transporter , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[35]  Willem Boogerd,et al.  Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  D. Goldstein,et al.  Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. , 2003, The New England journal of medicine.

[37]  T. Fojo,et al.  Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  M. Barrand,et al.  Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.

[39]  Armin Buschauer,et al.  Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. , 2002, The Journal of clinical investigation.

[40]  A. Sekine,et al.  Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR) , 2002, Journal of Human Genetics.

[41]  Jacques Fellay,et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.

[42]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[43]  M. Mayberg,et al.  Overexpression of Multiple Drug Resistance Genes in Endothelial Cells from Patients with Refractory Epilepsy , 2001, Epilepsia.

[44]  R. Hegele,et al.  ABCC6 gene polymorphism associated with variation in plasma lipoproteins , 2001, Journal of Human Genetics.

[45]  B. M. Forman,et al.  The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux , 2001, Nature Medicine.

[46]  S. Strom,et al.  Promiscuous regulator of xenobiotic removal , 2001, Nature Medicine.

[47]  R. Béliveau,et al.  Isolation of endothelial cells from brain, lung, and kidney: expression of the multidrug resistance P-glycoprotein isoforms. , 2001, Biochemical and biophysical research communications.

[48]  J. Drewe,et al.  Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. , 2000, Molecular pharmacology.

[49]  L. Möllgård,et al.  P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  F. Balis,et al.  Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates , 2000, Cancer Chemotherapy and Pharmacology.

[51]  R. Kim,et al.  P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. , 1999, Cancer research.

[52]  R. Bergmann,et al.  Mrp1 Multidrug Resistance‐Associated Protein and P‐Glycoprotein Expression in Rat Brain Microvessel Endothelial Cells , 1998, Journal of neurochemistry.

[53]  M. Barrand,et al.  Multidrug Resistance‐Related Transport Proteins in Isolated Human Brain Microvessels and in Cells Cultured from These Isolates , 1998, Journal of neurochemistry.

[54]  N. Barbaro,et al.  MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy , 1995, Epilepsia.